Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal korean women: A double-blind, randomized, placebo-controlled, multicenter study

Maturitas

Volumn 57, Issue 4, 2007, Pages 361-369

  Lee, B S ^a   Kang, B M ^b   Yoon, B K ^c   Choi, H ^d   Park, H M ^e   Kim, J G ^f  

^a Yonsei University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Inje University   (South Korea)

^e Chung Ang University College of Medicine   (South Korea)

^f Seoul National University   (South Korea)

Author keywords

Drospirenone; Estradiol; Hot flushes; Postmenopause

Indexed keywords

DROSPIRENONE PLUS ESTRADIOL; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GYNECOLOGICAL EXAMINATION; HOT FLUSH; HUMAN; KOREA; LABORATORY TEST; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MULTICENTER STUDY; NAUSEA; PHYSICAL EXAMINATION; POSTMENOPAUSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURGERY; THORAX PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL SYSTEM; VAGINA BLEEDING; VITAL SIGN;

AGED; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CLIMACTERIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; HOT FLASHES; HUMANS; KOREA; MENSTRUATION; MIDDLE AGED; POSTMENOPAUSE;

EID: 34447263795     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2007.03.004     Document Type: Article

References (16)

1. Witt D.M., and Lousberg T.R. Controversies surrounding estrogen use in postmenopausal women. Ann Pharmacother 31 (1997) 745-755
2. MacLennan A., Lester S., and Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systemic review. Climacteric 4 (2001) 58-74
3. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
4. Writing group for the Women's Health Initiative investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
5. The Women's Health Initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
6. Oelkers W. Drospirenone-a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 5 Suppl. 3 (2000) 17-24
7. Fuhrmann U., Krattenmacher R., Slater E.P., and Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54 (1996) 243-251
8. Muhn P., Fuhrmann U., Fritzemeier K.H., Krattenmacher R., and Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 761 (1995) 311-335
9. Stanczyk F.Z. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord 3 (2002) 211-224
10. Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric 6 Suppl. 2 (2003) 17-23
11. Elger W., Beier S., Pollow K., Garfield R., Shi S.O., and Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 68 (2003) 891-905
12. Foidart J.M. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 5 Suppl 3 (2000) 25-33
13. Schurmann R., Holler T., and Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 7 (2004) 189-196
14. Oelkers W., Foidart J.M., Dombrovicz N., Welter A., and Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80 (1995) 1816-1821
15. Warming L., Ravn P., Nielsen T., and Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 7 (2004) 103-111
16. Archer D.F., Thorneycroft I.H., Foegh M., et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 12 (2005) 716-727